nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—Autointegration results in viral DNA circles—HMGA1—muscle cancer	0.133	0.262	CbGpPWpGaD
L-DOPA—PSIP1—APOBEC3G mediated resistance to HIV-1 infection—HMGA1—muscle cancer	0.0884	0.174	CbGpPWpGaD
L-DOPA—PSIP1—2-LTR circle formation—HMGA1—muscle cancer	0.0676	0.133	CbGpPWpGaD
L-DOPA—PSIP1—Integration of provirus—HMGA1—muscle cancer	0.0553	0.109	CbGpPWpGaD
L-DOPA—PSIP1—Early Phase of HIV Life Cycle—HMGA1—muscle cancer	0.0388	0.0764	CbGpPWpGaD
L-DOPA—PSIP1—Vpr-mediated nuclear import of PICs—HMGA1—muscle cancer	0.0205	0.0404	CbGpPWpGaD
L-DOPA—PSIP1—Interactions of Vpr with host cellular proteins—HMGA1—muscle cancer	0.0191	0.0375	CbGpPWpGaD
L-DOPA—PSIP1—embryo—muscle cancer	0.0161	0.0808	CbGeAlD
L-DOPA—PSIP1—renal system—muscle cancer	0.0122	0.0612	CbGeAlD
L-DOPA—PSIP1—Podofilox—Etoposide—muscle cancer	0.0101	0.372	CbGdCrCtD
L-DOPA—PSIP1—Teniposide—Etoposide—muscle cancer	0.0101	0.372	CbGdCrCtD
L-DOPA—PSIP1—bone marrow—muscle cancer	0.00919	0.0463	CbGeAlD
L-DOPA—DDC—embryo—muscle cancer	0.00916	0.0461	CbGeAlD
L-DOPA—PSIP1—vagina—muscle cancer	0.00881	0.0443	CbGeAlD
L-DOPA—PSIP1—head—muscle cancer	0.00813	0.0409	CbGeAlD
L-DOPA—SLC7A8—renal system—muscle cancer	0.00801	0.0403	CbGeAlD
L-DOPA—PSIP1—testis—muscle cancer	0.00786	0.0396	CbGeAlD
L-DOPA—SLC7A8—Cell surface interactions at the vascular wall—ANGPT2—muscle cancer	0.00784	0.0154	CbGpPWpGaD
L-DOPA—PSIP1—Vinblastine—Vincristine—muscle cancer	0.00695	0.256	CbGdCrCtD
L-DOPA—DDC—renal system—muscle cancer	0.00693	0.0349	CbGeAlD
L-DOPA—SLC7A5—Cell surface interactions at the vascular wall—ANGPT2—muscle cancer	0.00684	0.0135	CbGpPWpGaD
L-DOPA—PSIP1—Host Interactions of HIV factors—HMGA1—muscle cancer	0.00669	0.0132	CbGpPWpGaD
L-DOPA—DRD4—testis—muscle cancer	0.00654	0.0329	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—muscle cancer	0.00645	0.0325	CbGeAlD
L-DOPA—PSIP1—HIV Life Cycle—HMGA1—muscle cancer	0.0063	0.0124	CbGpPWpGaD
L-DOPA—SLC7A8—tendon—muscle cancer	0.00625	0.0315	CbGeAlD
L-DOPA—SLC7A8—vagina—muscle cancer	0.0058	0.0292	CbGeAlD
L-DOPA—SLC7A5—cardiac atrium—muscle cancer	0.00556	0.028	CbGeAlD
L-DOPA—SLC7A8—head—muscle cancer	0.00536	0.027	CbGeAlD
L-DOPA—SLC7A8—testis—muscle cancer	0.00518	0.0261	CbGeAlD
L-DOPA—SLC15A1—renal system—muscle cancer	0.00515	0.0259	CbGeAlD
L-DOPA—SLC7A5—tendon—muscle cancer	0.00485	0.0244	CbGeAlD
L-DOPA—DRD3—head—muscle cancer	0.00476	0.024	CbGeAlD
L-DOPA—SLC7A5—bone marrow—muscle cancer	0.00469	0.0236	CbGeAlD
L-DOPA—DDC—head—muscle cancer	0.00464	0.0233	CbGeAlD
L-DOPA—SLC7A5—vagina—muscle cancer	0.0045	0.0226	CbGeAlD
L-DOPA—DDC—testis—muscle cancer	0.00448	0.0226	CbGeAlD
L-DOPA—DRD5—head—muscle cancer	0.00446	0.0225	CbGeAlD
L-DOPA—PSIP1—HIV Infection—HMGA1—muscle cancer	0.00435	0.00855	CbGpPWpGaD
L-DOPA—SLC7A5—head—muscle cancer	0.00415	0.0209	CbGeAlD
L-DOPA—SLC7A5—testis—muscle cancer	0.00401	0.0202	CbGeAlD
L-DOPA—SLC15A1—vagina—muscle cancer	0.00373	0.0188	CbGeAlD
L-DOPA—DDC—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00372	0.00731	CbGpPWpGaD
L-DOPA—SLC16A10—tendon—muscle cancer	0.00371	0.0187	CbGeAlD
L-DOPA—SLC16A10—vagina—muscle cancer	0.00344	0.0173	CbGeAlD
L-DOPA—DRD1—head—muscle cancer	0.00341	0.0172	CbGeAlD
L-DOPA—SLC16A10—testis—muscle cancer	0.00307	0.0155	CbGeAlD
L-DOPA—DDC—Tryptophan metabolism—MDM2—muscle cancer	0.00243	0.00477	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—ANGPT2—muscle cancer	0.00213	0.00418	CbGpPWpGaD
L-DOPA—DRD2—head—muscle cancer	0.00201	0.0101	CbGeAlD
L-DOPA—DRD2—testis—muscle cancer	0.00195	0.00979	CbGeAlD
L-DOPA—SLC7A5—Hemostasis—ANGPT2—muscle cancer	0.00185	0.00365	CbGpPWpGaD
L-DOPA—CYP2D6—renal system—muscle cancer	0.00181	0.0091	CbGeAlD
L-DOPA—DRD4—GPCRs, Other—CNR1—muscle cancer	0.0018	0.00355	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Other—CNR1—muscle cancer	0.0016	0.00315	CbGpPWpGaD
L-DOPA—Aminosalicylic Acid—PTGS2—muscle cancer	0.00159	0.56	CrCbGaD
L-DOPA—Dysphagia—Etoposide—muscle cancer	0.00155	0.00589	CcSEcCtD
L-DOPA—Blood disorder—Doxorubicin—muscle cancer	0.00153	0.00583	CcSEcCtD
L-DOPA—Hypoaesthesia—Vincristine—muscle cancer	0.00152	0.00579	CcSEcCtD
L-DOPA—Hallucination—Vincristine—muscle cancer	0.00152	0.00579	CcSEcCtD
L-DOPA—Alopecia—Dactinomycin—muscle cancer	0.00152	0.00576	CcSEcCtD
L-DOPA—Urinary tract disorder—Vincristine—muscle cancer	0.00151	0.00575	CcSEcCtD
L-DOPA—Sweating increased—Etoposide—muscle cancer	0.00151	0.00574	CcSEcCtD
L-DOPA—Urethral disorder—Vincristine—muscle cancer	0.0015	0.00571	CcSEcCtD
L-DOPA—Cardiovascular disorder—Doxorubicin—muscle cancer	0.00146	0.00555	CcSEcCtD
L-DOPA—Ill-defined disorder—Dactinomycin—muscle cancer	0.00139	0.00526	CcSEcCtD
L-DOPA—Anaemia—Dactinomycin—muscle cancer	0.00138	0.00524	CcSEcCtD
L-DOPA—Dyskinesia—Doxorubicin—muscle cancer	0.00136	0.00518	CcSEcCtD
L-DOPA—Acute coronary syndrome—Etoposide—muscle cancer	0.00136	0.00518	CcSEcCtD
L-DOPA—Myocardial infarction—Etoposide—muscle cancer	0.00136	0.00515	CcSEcCtD
L-DOPA—Neuropathy peripheral—Etoposide—muscle cancer	0.00136	0.00515	CcSEcCtD
L-DOPA—Alopecia—Vincristine—muscle cancer	0.00135	0.00515	CcSEcCtD
L-DOPA—Malaise—Dactinomycin—muscle cancer	0.00135	0.00512	CcSEcCtD
L-DOPA—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.00134	0.00264	CbGpPWpGaD
L-DOPA—Mental disorder—Vincristine—muscle cancer	0.00134	0.0051	CcSEcCtD
L-DOPA—Leukopenia—Dactinomycin—muscle cancer	0.00134	0.00508	CcSEcCtD
L-DOPA—Gait disturbance—Doxorubicin—muscle cancer	0.00131	0.00499	CcSEcCtD
L-DOPA—Musculoskeletal pain—Doxorubicin—muscle cancer	0.0013	0.00493	CcSEcCtD
L-DOPA—Agranulocytosis—Etoposide—muscle cancer	0.00129	0.0049	CcSEcCtD
L-DOPA—Back pain—Vincristine—muscle cancer	0.00129	0.0049	CcSEcCtD
L-DOPA—Hiccups—Doxorubicin—muscle cancer	0.00128	0.00487	CcSEcCtD
L-DOPA—Discomfort—Dactinomycin—muscle cancer	0.00126	0.00477	CcSEcCtD
L-DOPA—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00124	0.00473	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—muscle cancer	0.00124	0.44	CrCbGaD
L-DOPA—Hypoaesthesia—Etoposide—muscle cancer	0.00123	0.00469	CcSEcCtD
L-DOPA—Anaemia—Vincristine—muscle cancer	0.00123	0.00469	CcSEcCtD
L-DOPA—Urinary tract disorder—Etoposide—muscle cancer	0.00123	0.00466	CcSEcCtD
L-DOPA—Agitation—Vincristine—muscle cancer	0.00123	0.00466	CcSEcCtD
L-DOPA—Oedema—Dactinomycin—muscle cancer	0.00122	0.00463	CcSEcCtD
L-DOPA—Urethral disorder—Etoposide—muscle cancer	0.00122	0.00462	CcSEcCtD
L-DOPA—Blood urea increased—Doxorubicin—muscle cancer	0.00121	0.0046	CcSEcCtD
L-DOPA—CYP2D6—head—muscle cancer	0.00121	0.00609	CbGeAlD
L-DOPA—Leukopenia—Vincristine—muscle cancer	0.00119	0.00454	CcSEcCtD
L-DOPA—Thrombocytopenia—Dactinomycin—muscle cancer	0.00119	0.00453	CcSEcCtD
L-DOPA—PSIP1—Disease—ENO2—muscle cancer	0.00117	0.00231	CbGpPWpGaD
L-DOPA—CYP2D6—testis—muscle cancer	0.00117	0.00588	CbGeAlD
L-DOPA—Anorexia—Dactinomycin—muscle cancer	0.00116	0.00441	CcSEcCtD
L-DOPA—Convulsion—Vincristine—muscle cancer	0.00116	0.00439	CcSEcCtD
L-DOPA—Flushing—Etoposide—muscle cancer	0.00115	0.00438	CcSEcCtD
L-DOPA—Hypertension—Vincristine—muscle cancer	0.00115	0.00438	CcSEcCtD
L-DOPA—Alopecia—Etoposide—muscle cancer	0.0011	0.00417	CcSEcCtD
L-DOPA—Oedema—Vincristine—muscle cancer	0.00109	0.00414	CcSEcCtD
L-DOPA—Phlebitis—Doxorubicin—muscle cancer	0.00108	0.00411	CcSEcCtD
L-DOPA—Thrombocytopenia—Vincristine—muscle cancer	0.00107	0.00405	CcSEcCtD
L-DOPA—PSIP1—Disease—HMGA1—muscle cancer	0.00107	0.0021	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00106	0.00209	CbGpPWpGaD
L-DOPA—Decreased appetite—Dactinomycin—muscle cancer	0.00106	0.00403	CcSEcCtD
L-DOPA—Dysgeusia—Etoposide—muscle cancer	0.00106	0.00402	CcSEcCtD
L-DOPA—Hyperhidrosis—Vincristine—muscle cancer	0.00105	0.004	CcSEcCtD
L-DOPA—Fatigue—Dactinomycin—muscle cancer	0.00105	0.00399	CcSEcCtD
L-DOPA—Back pain—Etoposide—muscle cancer	0.00105	0.00397	CcSEcCtD
L-DOPA—Pain—Dactinomycin—muscle cancer	0.00104	0.00396	CcSEcCtD
L-DOPA—Vascular purpura—Doxorubicin—muscle cancer	0.00104	0.00395	CcSEcCtD
L-DOPA—Muscle spasms—Etoposide—muscle cancer	0.00104	0.00395	CcSEcCtD
L-DOPA—Anorexia—Vincristine—muscle cancer	0.00104	0.00394	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—IGF2—muscle cancer	0.00103	0.00203	CbGpPWpGaD
L-DOPA—Hypotension—Vincristine—muscle cancer	0.00102	0.00387	CcSEcCtD
L-DOPA—Ataxia—Methotrexate—muscle cancer	0.00101	0.00384	CcSEcCtD
L-DOPA—Feeling abnormal—Dactinomycin—muscle cancer	0.001	0.00382	CcSEcCtD
L-DOPA—Ill-defined disorder—Etoposide—muscle cancer	0.001	0.00381	CcSEcCtD
L-DOPA—Anaemia—Etoposide—muscle cancer	0.000999	0.0038	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000996	0.00379	CcSEcCtD
L-DOPA—Hot flush—Doxorubicin—muscle cancer	0.000995	0.00378	CcSEcCtD
L-DOPA—Menopausal symptoms—Doxorubicin—muscle cancer	0.000986	0.00375	CcSEcCtD
L-DOPA—Insomnia—Vincristine—muscle cancer	0.000985	0.00374	CcSEcCtD
L-DOPA—Paraesthesia—Vincristine—muscle cancer	0.000977	0.00372	CcSEcCtD
L-DOPA—Malaise—Etoposide—muscle cancer	0.000974	0.0037	CcSEcCtD
L-DOPA—Dermatitis bullous—Doxorubicin—muscle cancer	0.000974	0.0037	CcSEcCtD
L-DOPA—Leukopenia—Etoposide—muscle cancer	0.000967	0.00368	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—muscle cancer	0.000965	0.00367	CcSEcCtD
L-DOPA—Abdominal pain—Dactinomycin—muscle cancer	0.000963	0.00366	CcSEcCtD
L-DOPA—PSIP1—Disease—FOXO4—muscle cancer	0.000956	0.00188	CbGpPWpGaD
L-DOPA—Loss of consciousness—Etoposide—muscle cancer	0.00095	0.00361	CcSEcCtD
L-DOPA—Decreased appetite—Vincristine—muscle cancer	0.000946	0.0036	CcSEcCtD
L-DOPA—Cough—Etoposide—muscle cancer	0.000943	0.00358	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vincristine—muscle cancer	0.00094	0.00357	CcSEcCtD
L-DOPA—Fatigue—Vincristine—muscle cancer	0.000938	0.00357	CcSEcCtD
L-DOPA—Convulsion—Etoposide—muscle cancer	0.000936	0.00356	CcSEcCtD
L-DOPA—Hypertension—Etoposide—muscle cancer	0.000933	0.00355	CcSEcCtD
L-DOPA—Pain—Vincristine—muscle cancer	0.000931	0.00354	CcSEcCtD
L-DOPA—Constipation—Vincristine—muscle cancer	0.000931	0.00354	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000931	0.00354	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—muscle cancer	0.000931	0.00354	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—muscle cancer	0.000931	0.00354	CcSEcCtD
L-DOPA—Chest pain—Etoposide—muscle cancer	0.00092	0.0035	CcSEcCtD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00091	0.00179	CbGpPWpGaD
L-DOPA—Discomfort—Etoposide—muscle cancer	0.000909	0.00345	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—IGF2—muscle cancer	0.000902	0.00177	CbGpPWpGaD
L-DOPA—Hypersensitivity—Dactinomycin—muscle cancer	0.000898	0.00341	CcSEcCtD
L-DOPA—Gastrointestinal pain—Vincristine—muscle cancer	0.00089	0.00338	CcSEcCtD
L-DOPA—Confusional state—Etoposide—muscle cancer	0.000889	0.00338	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—muscle cancer	0.000875	0.00333	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—muscle cancer	0.000874	0.00332	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—muscle cancer	0.000872	0.00331	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—muscle cancer	0.000863	0.00328	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000863	0.00328	CcSEcCtD
L-DOPA—Abdominal pain—Vincristine—muscle cancer	0.000861	0.00327	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—muscle cancer	0.000852	0.00324	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00085	0.00323	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—CNR1—muscle cancer	0.000845	0.00166	CbGpPWpGaD
L-DOPA—Anorexia—Etoposide—muscle cancer	0.000841	0.00319	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—muscle cancer	0.000834	0.00317	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—muscle cancer	0.000832	0.00316	CcSEcCtD
L-DOPA—Depression—Methotrexate—muscle cancer	0.000826	0.00314	CcSEcCtD
L-DOPA—Hypotension—Etoposide—muscle cancer	0.000824	0.00313	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—muscle cancer	0.000824	0.00313	CcSEcCtD
L-DOPA—DRD5—GPCR ligand binding—PTCH1—muscle cancer	0.000821	0.00162	CbGpPWpGaD
L-DOPA—Dysphagia—Doxorubicin—muscle cancer	0.000804	0.00306	CcSEcCtD
L-DOPA—Hypersensitivity—Vincristine—muscle cancer	0.000802	0.00305	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—muscle cancer	0.000792	0.00301	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—muscle cancer	0.000786	0.00299	CcSEcCtD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000784	0.00154	CbGpPWpGaD
L-DOPA—Somnolence—Etoposide—muscle cancer	0.000784	0.00298	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—muscle cancer	0.000783	0.00298	CcSEcCtD
L-DOPA—Asthenia—Vincristine—muscle cancer	0.000781	0.00297	CcSEcCtD
L-DOPA—DDC—Metabolism—FH—muscle cancer	0.000776	0.00153	CbGpPWpGaD
L-DOPA—Vomiting—Dactinomycin—muscle cancer	0.000775	0.00294	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—muscle cancer	0.000773	0.00294	CcSEcCtD
L-DOPA—Rash—Dactinomycin—muscle cancer	0.000768	0.00292	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—muscle cancer	0.000767	0.00291	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—muscle cancer	0.000761	0.00289	CcSEcCtD
L-DOPA—Fatigue—Etoposide—muscle cancer	0.00076	0.00289	CcSEcCtD
L-DOPA—Pain—Etoposide—muscle cancer	0.000754	0.00287	CcSEcCtD
L-DOPA—Constipation—Etoposide—muscle cancer	0.000754	0.00287	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—CNR1—muscle cancer	0.000751	0.00148	CbGpPWpGaD
L-DOPA—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000747	0.00284	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—muscle cancer	0.000747	0.00284	CcSEcCtD
L-DOPA—Diarrhoea—Vincristine—muscle cancer	0.000745	0.00283	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—muscle cancer	0.000743	0.00283	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—muscle cancer	0.000743	0.00282	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—muscle cancer	0.000734	0.00279	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—muscle cancer	0.000732	0.00278	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—muscle cancer	0.000729	0.00277	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—muscle cancer	0.000728	0.00277	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—muscle cancer	0.000727	0.00276	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—muscle cancer	0.000724	0.00275	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—muscle cancer	0.000721	0.00274	CcSEcCtD
L-DOPA—Dizziness—Vincristine—muscle cancer	0.00072	0.00274	CcSEcCtD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000706	0.00139	CbGpPWpGaD
L-DOPA—PSIP1—Disease—FOXO1—muscle cancer	0.000706	0.00139	CbGpPWpGaD
L-DOPA—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000703	0.00267	CcSEcCtD
L-DOPA—Urticaria—Etoposide—muscle cancer	0.000701	0.00266	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—muscle cancer	0.000697	0.00265	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—muscle cancer	0.000697	0.00265	CcSEcCtD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000697	0.00137	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000693	0.00136	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CNR1—muscle cancer	0.000693	0.00136	CbGpPWpGaD
L-DOPA—Vomiting—Vincristine—muscle cancer	0.000692	0.00263	CcSEcCtD
L-DOPA—Rash—Vincristine—muscle cancer	0.000686	0.00261	CcSEcCtD
L-DOPA—Dermatitis—Vincristine—muscle cancer	0.000686	0.00261	CcSEcCtD
L-DOPA—Headache—Vincristine—muscle cancer	0.000682	0.00259	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000672	0.00132	CbGpPWpGaD
L-DOPA—Agranulocytosis—Doxorubicin—muscle cancer	0.000669	0.00254	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—muscle cancer	0.000657	0.0025	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—muscle cancer	0.000651	0.00248	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—muscle cancer	0.00065	0.00247	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—muscle cancer	0.000647	0.00246	CcSEcCtD
L-DOPA—Nausea—Vincristine—muscle cancer	0.000647	0.00246	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—muscle cancer	0.000645	0.00245	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—muscle cancer	0.000644	0.00245	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—muscle cancer	0.000641	0.00243	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—muscle cancer	0.000636	0.00242	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—muscle cancer	0.000634	0.00241	CcSEcCtD
L-DOPA—Asthenia—Etoposide—muscle cancer	0.000633	0.0024	CcSEcCtD
L-DOPA—DRD5—Signaling Pathways—KIDINS220—muscle cancer	0.000632	0.00124	CbGpPWpGaD
L-DOPA—Urethral disorder—Doxorubicin—muscle cancer	0.000631	0.0024	CcSEcCtD
L-DOPA—Back pain—Methotrexate—muscle cancer	0.000626	0.00238	CcSEcCtD
L-DOPA—Pruritus—Etoposide—muscle cancer	0.000624	0.00237	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—muscle cancer	0.00061	0.00232	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—PTCH1—muscle cancer	0.000606	0.00119	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000605	0.00119	CbGpPWpGaD
L-DOPA—Diarrhoea—Etoposide—muscle cancer	0.000603	0.00229	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—muscle cancer	0.0006	0.00228	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—muscle cancer	0.000598	0.00227	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—muscle cancer	0.000597	0.00227	CcSEcCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000597	0.00117	CbGpPWpGaD
L-DOPA—Malaise—Methotrexate—muscle cancer	0.000584	0.00222	CcSEcCtD
L-DOPA—Dizziness—Etoposide—muscle cancer	0.000583	0.00222	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—muscle cancer	0.000579	0.0022	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—muscle cancer	0.000575	0.00219	CcSEcCtD
L-DOPA—DRD2—G alpha (i) signalling events—CNR1—muscle cancer	0.000574	0.00113	CbGpPWpGaD
L-DOPA—Alopecia—Doxorubicin—muscle cancer	0.000569	0.00216	CcSEcCtD
L-DOPA—Cough—Methotrexate—muscle cancer	0.000565	0.00215	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—muscle cancer	0.000564	0.00214	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—muscle cancer	0.000561	0.00213	CcSEcCtD
L-DOPA—Vomiting—Etoposide—muscle cancer	0.000561	0.00213	CcSEcCtD
L-DOPA—Rash—Etoposide—muscle cancer	0.000556	0.00211	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—muscle cancer	0.000555	0.00211	CcSEcCtD
L-DOPA—Headache—Etoposide—muscle cancer	0.000552	0.0021	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—muscle cancer	0.000552	0.0021	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—muscle cancer	0.000551	0.00209	CcSEcCtD
L-DOPA—Tension—Doxorubicin—muscle cancer	0.00055	0.00209	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—muscle cancer	0.000549	0.00209	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—PTCH1—muscle cancer	0.000546	0.00107	CbGpPWpGaD
L-DOPA—Discomfort—Methotrexate—muscle cancer	0.000544	0.00207	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—muscle cancer	0.000544	0.00207	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—muscle cancer	0.000542	0.00206	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—muscle cancer	0.000539	0.00205	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—PTCH1—muscle cancer	0.000538	0.00106	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KIT—muscle cancer	0.000538	0.00106	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000533	0.00105	CbGpPWpGaD
L-DOPA—Confusional state—Methotrexate—muscle cancer	0.000533	0.00202	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—muscle cancer	0.000528	0.00201	CcSEcCtD
L-DOPA—Nausea—Etoposide—muscle cancer	0.000524	0.00199	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—muscle cancer	0.00052	0.00198	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—muscle cancer	0.000518	0.00197	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—muscle cancer	0.000517	0.00197	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—muscle cancer	0.000515	0.00196	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—CNR1—muscle cancer	0.000512	0.00101	CbGpPWpGaD
L-DOPA—Hyperhidrosis—Methotrexate—muscle cancer	0.000511	0.00194	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—muscle cancer	0.000505	0.00192	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—muscle cancer	0.000503	0.00191	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—muscle cancer	0.000503	0.00191	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—muscle cancer	0.000502	0.00191	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—muscle cancer	0.000495	0.00188	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—muscle cancer	0.000494	0.00188	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—muscle cancer	0.000493	0.00187	CcSEcCtD
L-DOPA—Cough—Doxorubicin—muscle cancer	0.000489	0.00186	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—muscle cancer	0.000486	0.00185	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—muscle cancer	0.000484	0.00184	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—muscle cancer	0.000478	0.00182	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—muscle cancer	0.000477	0.00181	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—muscle cancer	0.000475	0.00181	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—muscle cancer	0.000474	0.0018	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—muscle cancer	0.000471	0.00179	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—muscle cancer	0.000471	0.00179	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—muscle cancer	0.00047	0.00178	CcSEcCtD
L-DOPA—DRD4—Signaling Pathways—KIDINS220—muscle cancer	0.000467	0.000918	CbGpPWpGaD
L-DOPA—Dry mouth—Doxorubicin—muscle cancer	0.000467	0.00177	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—muscle cancer	0.000465	0.00177	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—muscle cancer	0.000461	0.00175	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—CNR1—muscle cancer	0.000461	0.000906	CbGpPWpGaD
L-DOPA—Decreased appetite—Methotrexate—muscle cancer	0.000459	0.00175	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—muscle cancer	0.000457	0.00174	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000457	0.000898	CbGpPWpGaD
L-DOPA—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000456	0.00173	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—muscle cancer	0.000455	0.00173	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—CNR1—muscle cancer	0.000454	0.000894	CbGpPWpGaD
L-DOPA—Pain—Methotrexate—muscle cancer	0.000452	0.00172	CcSEcCtD
L-DOPA—Shock—Doxorubicin—muscle cancer	0.00045	0.00171	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—muscle cancer	0.000448	0.0017	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—muscle cancer	0.000442	0.00168	CcSEcCtD
L-DOPA—DDC—Metabolism—MED12—muscle cancer	0.000438	0.000863	CbGpPWpGaD
L-DOPA—Anorexia—Doxorubicin—muscle cancer	0.000436	0.00166	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—muscle cancer	0.000435	0.00165	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—VEGFA—muscle cancer	0.000433	0.000853	CbGpPWpGaD
L-DOPA—Gastrointestinal pain—Methotrexate—muscle cancer	0.000432	0.00164	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—TP53—muscle cancer	0.000428	0.000841	CbGpPWpGaD
L-DOPA—Hypotension—Doxorubicin—muscle cancer	0.000427	0.00162	CcSEcCtD
L-DOPA—PSIP1—Disease—MDM2—muscle cancer	0.000424	0.000833	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTCH1—muscle cancer	0.000421	0.000829	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIDINS220—muscle cancer	0.00042	0.000827	CbGpPWpGaD
L-DOPA—Urticaria—Methotrexate—muscle cancer	0.00042	0.00159	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—muscle cancer	0.000418	0.00159	CcSEcCtD
L-DOPA—DRD3—Signaling Pathways—KIDINS220—muscle cancer	0.000415	0.000816	CbGpPWpGaD
L-DOPA—Insomnia—Doxorubicin—muscle cancer	0.000414	0.00157	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—PTCH1—muscle cancer	0.000412	0.000811	CbGpPWpGaD
L-DOPA—Paraesthesia—Doxorubicin—muscle cancer	0.000411	0.00156	CcSEcCtD
L-DOPA—PSIP1—Disease—PTGS2—muscle cancer	0.000408	0.000803	CbGpPWpGaD
L-DOPA—Dyspnoea—Doxorubicin—muscle cancer	0.000408	0.00155	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—muscle cancer	0.000407	0.00155	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—muscle cancer	0.000403	0.00153	CcSEcCtD
L-DOPA—DDC—Metabolism—ENO2—muscle cancer	0.0004	0.000786	CbGpPWpGaD
L-DOPA—Decreased appetite—Doxorubicin—muscle cancer	0.000398	0.00151	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000395	0.0015	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—muscle cancer	0.000394	0.0015	CcSEcCtD
L-DOPA—DRD5—GPCR downstream signaling—CNR1—muscle cancer	0.000392	0.000771	CbGpPWpGaD
L-DOPA—Pain—Doxorubicin—muscle cancer	0.000391	0.00149	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—muscle cancer	0.000391	0.00149	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—muscle cancer	0.000389	0.00148	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—muscle cancer	0.000379	0.00144	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—VEGFA—muscle cancer	0.000378	0.000744	CbGpPWpGaD
L-DOPA—Feeling abnormal—Doxorubicin—muscle cancer	0.000377	0.00143	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000374	0.00142	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—muscle cancer	0.000374	0.00142	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—muscle cancer	0.000363	0.00138	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—muscle cancer	0.000362	0.00137	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—muscle cancer	0.000361	0.00137	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—CNR1—muscle cancer	0.000356	0.0007	CbGpPWpGaD
L-DOPA—Dizziness—Methotrexate—muscle cancer	0.000349	0.00133	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—CNR1—muscle cancer	0.000348	0.000684	CbGpPWpGaD
L-DOPA—Hypersensitivity—Doxorubicin—muscle cancer	0.000337	0.00128	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—muscle cancer	0.000336	0.00128	CcSEcCtD
L-DOPA—Rash—Methotrexate—muscle cancer	0.000333	0.00127	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—muscle cancer	0.000333	0.00126	CcSEcCtD
L-DOPA—Headache—Methotrexate—muscle cancer	0.000331	0.00126	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—muscle cancer	0.000328	0.00125	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—TP53—muscle cancer	0.000327	0.000644	CbGpPWpGaD
L-DOPA—Pruritus—Doxorubicin—muscle cancer	0.000324	0.00123	CcSEcCtD
L-DOPA—DRD2—Signaling Pathways—KIDINS220—muscle cancer	0.000317	0.000624	CbGpPWpGaD
L-DOPA—Nausea—Methotrexate—muscle cancer	0.000314	0.00119	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—muscle cancer	0.000313	0.00119	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—PTCH1—muscle cancer	0.000311	0.000612	CbGpPWpGaD
L-DOPA—Dizziness—Doxorubicin—muscle cancer	0.000302	0.00115	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—muscle cancer	0.000291	0.00111	CcSEcCtD
L-DOPA—DRD4—GPCR downstream signaling—CNR1—muscle cancer	0.000289	0.000569	CbGpPWpGaD
L-DOPA—Rash—Doxorubicin—muscle cancer	0.000288	0.0011	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—muscle cancer	0.000288	0.0011	CcSEcCtD
L-DOPA—Headache—Doxorubicin—muscle cancer	0.000287	0.00109	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—TP53—muscle cancer	0.000286	0.000562	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTCH1—muscle cancer	0.00028	0.000551	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTCH1—muscle cancer	0.000276	0.000544	CbGpPWpGaD
L-DOPA—Nausea—Doxorubicin—muscle cancer	0.000272	0.00103	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—CNR1—muscle cancer	0.000263	0.000517	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CNR1—muscle cancer	0.00026	0.000512	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CNR1—muscle cancer	0.000257	0.000505	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTCH1—muscle cancer	0.000249	0.00049	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—muscle cancer	0.000248	0.000488	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CNR1—muscle cancer	0.000236	0.000465	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CNR1—muscle cancer	0.000233	0.000459	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—muscle cancer	0.000223	0.000439	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—muscle cancer	0.00022	0.000434	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FOXO4—muscle cancer	0.000214	0.000421	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH1—muscle cancer	0.000211	0.000416	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CNR1—muscle cancer	0.00021	0.000413	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CNR1—muscle cancer	0.000197	0.000387	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH1—muscle cancer	0.000184	0.000362	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CNR1—muscle cancer	0.000178	0.000351	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—FH—muscle cancer	0.000178	0.000351	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF2—muscle cancer	0.000172	0.000338	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—muscle cancer	0.000169	0.000332	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH1—muscle cancer	0.000165	0.000325	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH1—muscle cancer	0.000163	0.000321	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FOXO1—muscle cancer	0.000158	0.000311	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FOXO4—muscle cancer	0.000158	0.000311	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CNR1—muscle cancer	0.000155	0.000305	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FOXO4—muscle cancer	0.000142	0.00028	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FOXO4—muscle cancer	0.00014	0.000276	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CNR1—muscle cancer	0.00014	0.000275	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—muscle cancer	0.000139	0.000274	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CNR1—muscle cancer	0.000138	0.000271	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF2—muscle cancer	0.000127	0.000249	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH1—muscle cancer	0.000125	0.000246	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KIT—muscle cancer	0.00012	0.000237	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FOXO1—muscle cancer	0.000117	0.00023	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF2—muscle cancer	0.000114	0.000225	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF2—muscle cancer	0.000113	0.000222	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FOXO4—muscle cancer	0.000107	0.000211	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CNR1—muscle cancer	0.000105	0.000207	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FOXO1—muscle cancer	0.000105	0.000207	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FOXO1—muscle cancer	0.000104	0.000204	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MED12—muscle cancer	0.000101	0.000198	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MDM2—muscle cancer	9.49e-05	0.000187	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—muscle cancer	9.19e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KIT—muscle cancer	8.89e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF2—muscle cancer	8.62e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—muscle cancer	8e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FOXO1—muscle cancer	7.93e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—muscle cancer	7.9e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—muscle cancer	7.21e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—muscle cancer	7e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—muscle cancer	6.3e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—muscle cancer	6.22e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—muscle cancer	6.04e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—muscle cancer	5.44e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—muscle cancer	5.32e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—muscle cancer	4.79e-05	9.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—muscle cancer	4.76e-05	9.36e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—muscle cancer	4.72e-05	9.29e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—muscle cancer	4.02e-05	7.91e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—muscle cancer	3.62e-05	7.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—muscle cancer	3.61e-05	7.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—muscle cancer	3.57e-05	7.02e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—muscle cancer	3.2e-05	6.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—muscle cancer	2.73e-05	5.37e-05	CbGpPWpGaD
